Recursion Pharmaceuticals AI Platform

Recursion Pharmaceuticals' AI platform, combining robotics and high-content imaging, tests 2.2 million compound-disease combinations per week — a throughput 1,000x greater than traditional drug discovery. This efficiency led to REC-994 for cerebral cavernous malformation entering Phase II trials as the first fully AI-discovered neurological drug candidate. In 2025, the platform identified a repurposing opportunity for a cancer drug, cutting preclinical timelines by 60% compared to the industry average of 5-7 years, and it now screens over 100,000 compounds monthly faster than #7 Google Med-PaLM 2 can process diagnostic queries, showcasing its unmatched scale in target identification.